Novo Nordisk A/S banner

Novo Nordisk A/S
F:NOVC

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
F:NOVC
Watchlist
Price: 90.7 EUR -1.52% Market Closed
Market Cap: €203.5B

Relative Value

The Relative Value of one NOVC stock under the Base Case scenario is hidden EUR. Compared to the current market price of 90.7 EUR, Novo Nordisk A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVC Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

NOVC Competitors Multiples
Novo Nordisk A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
F:NOVC
1.1T EUR 3.5 10.7 7.9 9.3
US
Eli Lilly and Co
NYSE:LLY
987B USD 15.1 47.8 32.2 34.3
US
Johnson & Johnson
NYSE:JNJ
592.7B USD 6.3 22.1 15.3 18.9
CH
Roche Holding AG
SIX:ROG
298.4B CHF 4.9 31.7 13.3 15.6
UK
AstraZeneca PLC
LSE:AZN
237.8B GBP 5.5 31.8 17.5 24.6
CH
Novartis AG
SIX:NOVN
248.3B CHF 5.7 22.8 14 18.1
US
Merck & Co Inc
NYSE:MRK
309B USD 4.8 16.9 10.6 12.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
154.4B USD 2.5 19.9 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
124.1B USD 2.6 17.6 7.4 9.1
UK
GlaxoSmithKline PLC
LSE:GSK
89.8B GBP 2.7 15.7 7.9 11.2
P/E Multiple
Earnings Growth PEG
DK
Novo Nordisk A/S
F:NOVC
Average P/E: 23.7
10.7
7%
1.5
US
Eli Lilly and Co
NYSE:LLY
47.8
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22.1
7%
3.2
CH
Roche Holding AG
SIX:ROG
31.7
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.8
26%
1.2
CH
Novartis AG
SIX:NOVN
22.8
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.9
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
19.9
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.6
17%
1
UK
GlaxoSmithKline PLC
LSE:GSK
15.7
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
F:NOVC
Average EV/EBITDA: 42.4
7.9
7%
1.1
US
Eli Lilly and Co
NYSE:LLY
32.2
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.7
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
17.5
11%
1.6
CH
Novartis AG
SIX:NOVN
14
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.6
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-12%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
7.9
2%
4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
F:NOVC
Average EV/EBIT: 90.8
9.3
8%
1.2
US
Eli Lilly and Co
NYSE:LLY
34.3
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.9
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.6
6%
2.6
UK
AstraZeneca PLC
LSE:AZN
24.6
24%
1
CH
Novartis AG
SIX:NOVN
18.1
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.4
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.1
-6%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
11.2
12%
0.9